STOCK TITAN
  1. Home
  2. Sec-filings
  3. MLYS
  4. [Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Mineralys Therapeutics (MLYS) director receives stock options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Karydas Daphne reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. director Daphne Karydas reported equity awards consisting of stock options and restricted stock units. She was granted stock options for 8,300 shares at a price of $0.00 per share, vesting in 12 substantially equal monthly installments following the grant date.

She also received 6,200 restricted stock units (RSUs)

Positive

  • None.

Negative

  • None.
Insider Karydas Daphne
Role Director
Type Security Shares Price Value
Grant/Award Stock Option 8,300 $0.00 --
Grant/Award Common Stock 6,200 $0.00 --
Holdings After Transaction: Stock Option — 8,300 shares (Direct); Common Stock — 6,200 shares (Direct)
Footnotes (1)
  1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. The stock option vests in 12 substantially equal monthly installments following the date of grant.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Karydas Daphne
(Last) (First) (Middle)
150 N. RADNOR CHESTER RD.
SUITE F200
(Street)
RADNOR PA 19087
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/19/2026 A 6,200(1) A $0 6,200 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $28.06 02/19/2026 A 8,300 (2) 02/19/2036 Common Stock 8,300 $0 8,300 D
Explanation of Responses:
1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
2. The stock option vests in 12 substantially equal monthly installments following the date of grant.
Remarks:
/s/ Adam Levy, Attorney-in-fact 02/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Daphne Karydas report for MLYS?

Daphne Karydas reported equity awards in Mineralys Therapeutics, Inc. She received 8,300 stock options and 6,200 restricted stock units, both granted for no cash consideration as part of her director compensation on the reported grant date.

How many stock options were granted to the Mineralys Therapeutics director?

The director received 8,300 stock options in Mineralys Therapeutics, Inc. These options were granted with a price of $0.00 per share and vest in 12 substantially equal monthly installments following the grant date, aligning compensation with ongoing board service.

What are the terms of the RSU grant reported by MLYS?

The filing shows a grant of 6,200 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Mineralys Therapeutics common stock, vesting in a single annual installment following the grant date, subject to continued service conditions.

Is the Form 4 transaction for Mineralys Therapeutics a purchase or an award?

The Form 4 reports equity awards, not open-market purchases. Both the 8,300 stock options and 6,200 RSUs were granted for no additional cash consideration as part of compensation, classified as grant or award acquisitions in the transaction details.

How do the Mineralys stock options granted to the director vest?

The stock options granted to the director vest over time. According to the filing, the 8,300 options vest in 12 substantially equal monthly installments following the grant date, gradually increasing the director’s exercisable option position throughout the first year.

When will the Mineralys RSUs reported in the Form 4 vest?

The RSUs vest in a single step after one year. The filing states that the 6,200 restricted stock units vest in one annual installment following the grant date, after which each vested RSU converts into one share of common stock.